|
May 2
|
Codexis Inc (CDXS) Q1 2024 Earnings: Surpasses Revenue Forecasts with Strategic Advances
|
|
May 2
|
Codexis Reports First Quarter 2024 Financial Results
|
|
Apr 26
|
With 74% institutional ownership, Codexis, Inc. (NASDAQ:CDXS) is a favorite amongst the big guns
|
|
Apr 18
|
Codexis to Report First Quarter 2024 Financial Results on May 2
|
|
Apr 11
|
Codexis Appoints Carole Cobb, MBA, to Strategic Advisory Board
|
|
Mar 30
|
Favourable Signals For Codexis: Numerous Insiders Acquired Stock
|
|
Jan 14
|
The past three years for Codexis (NASDAQ:CDXS) investors has not been profitable
|
|
Jan 9
|
Baillie Gifford Trims Position in Codexis Inc
|
|
Dec 27
|
Codexis Announces Purchase Agreement with Nestlé Health Science for CDX-7108
|
|
Dec 18
|
Codexis, Inc. (NASDAQ:CDXS) Stock Rockets 41% But Many Are Still Ignoring The Company
|
|
Nov 30
|
Codexis, Inc.'s (NASDAQ:CDXS) Intrinsic Value Is Potentially 92% Above Its Share Price
|
|
Nov 29
|
3 Synthetic Biology Stocks Likely to Mint New Millionaires
|
|
Nov 28
|
Codexis to Host Virtual KOL Event on its ECO Synthesis™ Platform and the Future of RNAi Therapeutics Manufacturing on December 8, 2023
|
|
Nov 13
|
Codexis, Inc. (NASDAQ:CDXS) is largely controlled by institutional shareholders who own 74% of the company
|
|
Nov 3
|
Q3 2023 Codexis Inc Earnings Call
|
|
Nov 3
|
Codexis, Inc. (NASDAQ:CDXS) Q3 2023 Earnings Call Transcript
|
|
Nov 2
|
Codexis Inc (CDXS) Reports Q3 2023 Financial Results: Net Loss of $34.9 Million
|
|
Nov 2
|
Codexis Reports Third Quarter 2023 Financial Results
|
|
Oct 27
|
Codexis to Present Update on ECO Synthesis™ Platform at TIDES Europe
|
|
Oct 21
|
Companies Like Codexis (NASDAQ:CDXS) Are In A Position To Invest In Growth
|